Track topics on Twitter Track topics that are important to you
Here are the most relevant search results for "Lipocine resubmits LPCN 1021 hypogonadism" found in our extensive corporate database of over 50,000 company records.
Lipocine Inc. is a specialty pharmaceutical company developing innovative products for use in menâs and womenâs health using its proprietary drug delivery technologies. Lipocineâs lead product candidate, LPCN 1021, is Phase III ready and is targeted to treat symptoms of low testosterone for men in need of testosterone replacement therapy. Th...
Lipocine Inc. is a pharmaceutical company leveraging its proprietary drug delivery technologies to commercialize innovative pharmaceutical products. Lipocine improves established drugs to enable products with patient friendly attributes. Lipocine is currently focused on developing innovative oral versions of several hormones for use in men and womenâs ...
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSanteâs lead products include LibiGelÂ® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD) which is in Phase III clinical development under a U.S. Food and Drug Administration (FDA) Special Protocol...
Founded in 2014, Aspen Park Pharmaceuticals, Inc. is a privately held therapeutics company that focuses on the development of menâs health therapies for important medical diseases and conditions. The menâs health therapeutics market is estimated to be $10 billion worldwide. Two urologists, Dr. Harry Fisch and Dr. Mitchell Steiner, cofounded the c...
Pharmacy Act 1948 came into force in Andhra State in the year 1955. The States re-organization took place in November, 1956. The Andhra Pradesh State has been formed with certain parts of erstwhile Hyderabad State (Telangana) with Hyderabad as Capital. The Pharmacy Act has been extended to Telangana area with effect from 01.09.1960. Under Section 46 of Pharmacy Act 1948 rules were framed vide G.O....
Columbia Laboratories, Inc. is focused on developing products that utilize its novel bioadhesive drug delivery technologies to optimize drug delivery in a controlled, sustained manner. The Company's strategy is to fund new development projects through proof of concept, then partner for later-stage clinical development and commercialization. CRINONEÂ® 8% ...
BioLineRx Ltd. is a publicly-traded biopharmaceutical development company. It is dedicated to building a portfolio of products for unmet medical needs or with advantages over currently available therapies. BioLineRxâs current portfolio consists of five clinical stage candidates: BL-1020 for schizophrenia has commenced a Phase II/III study; BL-1040 for...
BioSanteâs corporate strategy is to develop high value medically-needed pharmaceutical products and to implement strategic alternatives with respect to its products and its company, including licenses, business collaborations and other business combinations or transactions with other pharmaceutical and biotechnology companies. BioSanteâs products ...